ID   STK4_HUMAN              Reviewed;         487 AA.
AC   Q13043; B2RCR8; Q15802; Q4G156; Q5H982; Q6PD60; Q9BR32; Q9NTZ4;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Serine/threonine-protein kinase 4;
DE            EC=2.7.11.1;
DE   AltName: Full=Mammalian STE20-like protein kinase 1;
DE            Short=MST-1;
DE   AltName: Full=STE20-like kinase MST1;
DE   AltName: Full=Serine/threonine-protein kinase Krs-2;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 4 37kDa subunit;
DE              Short=MST1/N;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 4 18kDa subunit;
DE              Short=MST1/C;
GN   Name=STK4; Synonyms=KRS2, MST1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-312.
RX   PubMed=7665586; DOI=10.1074/jbc.270.37.21695;
RA   Creasy C.L., Chernoff J.;
RT   "Cloning and characterization of a human protein kinase with homology
RT   to Ste20.";
RL   J. Biol. Chem. 270:21695-21700(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8816758; DOI=10.1073/pnas.93.19.10099;
RA   Taylor L.K., Wang H.C., Erikson R.L.;
RT   "Newly identified stress-responsive protein kinases, Krs-1 and Krs-
RT   2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10099-10104(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone, Brain, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-7; 16-94; 118-144; 152-181; 232-259; 270-282;
RP   292-301; 333-342; 384-402; 405-413; 421-465 AND 470-481, ACETYLATION
RP   AT MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Mammary carcinoma;
RA   Bienvenut W.V., Matallanas D., Cooper W.N., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   FUNCTION, HOMODIMERIZATION, AND ENZYME REGULATION.
RX   PubMed=8702870; DOI=10.1074/jbc.271.35.21049;
RA   Creasy C.L., Ambrose D.M., Chernoff J.;
RT   "The Ste20-like protein kinase, Mst1, dimerizes and contains an
RT   inhibitory domain.";
RL   J. Biol. Chem. 271:21049-21053(1996).
RN   [9]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ASP-326 AND ASP-349.
RX   PubMed=11278283; DOI=10.1074/jbc.M005109200;
RA   Lee K.-K., Ohyama T., Yajima N., Tsubuki S., Yonehara S.;
RT   "MST, a physiological caspase substrate, highly sensitizes apoptosis
RT   both upstream and downstream of caspase activation.";
RL   J. Biol. Chem. 276:19276-19285(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11517310; DOI=10.1073/pnas.181161698;
RA   Ura S., Masuyama N., Graves J.D., Gotoh Y.;
RT   "Caspase cleavage of MST1 promotes nuclear translocation and chromatin
RT   condensation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10148-10153(2001).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H2B.
RX   PubMed=12757711; DOI=10.1016/S0092-8674(03)00355-6;
RA   Cheung W.L., Ajiro K., Samejima K., Kloc M., Cheung P., Mizzen C.A.,
RA   Beeser A., Etkin L.D., Chernoff J., Earnshaw W.C., Allis C.D.;
RT   "Apoptotic phosphorylation of histone H2B is mediated by mammalian
RT   sterile twenty kinase.";
RL   Cell 113:507-517(2003).
RN   [12]
RP   FUNCTION, ENZYME REGULATION, HOMODIMERIZATION, PHOSPHORYLATION AT
RP   THR-183, MUTAGENESIS OF LYS-59; THR-175; THR-177; THR-183 AND LEU-444,
RP   AND INTERACTION WITH RASSF1 AND NORE1.
RX   PubMed=15109305; DOI=10.1042/BJ20040025;
RA   Praskova M., Khoklatchev A., Ortiz-Vega S., Avruch J.;
RT   "Regulation of the MST1 kinase by autophosphorylation, by the growth
RT   inhibitory proteins, RASSF1 and NORE1, and by Ras.";
RL   Biochem. J. 381:453-462(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH RASSF1.
RX   PubMed=16510573; DOI=10.1158/0008-5472.CAN-05-2951;
RA   Oh H.J., Lee K.-K., Song S.J., Jin M.S., Song M.S., Lee J.H., Im C.R.,
RA   Lee J.-O., Yonehara S., Lim D.-S.;
RT   "Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis.";
RL   Cancer Res. 66:2562-2569(2006).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH FOXO3.
RX   PubMed=16751106; DOI=10.1016/j.cell.2006.03.046;
RA   Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B.E.,
RA   DiBacco S., de la Iglesia N., Gygi S.P., Blackwell T.K., Bonni A.;
RT   "A conserved MST-FOXO signaling pathway mediates oxidative-stress
RT   responses and extends life span.";
RL   Cell 125:987-1001(2006).
RN   [15]
RP   INTERACTION WITH SAV1, FUNCTION, AND MUTAGENESIS OF LYS-59.
RX   PubMed=16930133; DOI=10.1111/j.1742-4658.2006.05427.x;
RA   Callus B.A., Verhagen A.M., Vaux D.L.;
RT   "Association of mammalian sterile twenty kinases, Mst1 and Mst2, with
RT   hSalvador via C-terminal coiled-coil domains, leads to its
RT   stabilization and phosphorylation.";
RL   FEBS J. 273:4264-4276(2006).
RN   [16]
RP   FUNCTION, INTERACTION WITH PKB/AKT1, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=17932490; DOI=10.1038/sj.emboj.7601872;
RA   Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N.,
RA   Rubin M.A., Yelick P.C., Freeman M.R.;
RT   "The pro-apoptotic kinase Mst1 and its caspase cleavage products are
RT   direct inhibitors of Akt1.";
RL   EMBO J. 26:4523-4534(2007).
RN   [17]
RP   PHOSPHORYLATION AT THR-387, AND INTERACTION WITH PKB/AKT1.
RX   PubMed=17726016; DOI=10.1074/jbc.M704542200;
RA   Jang S.W., Yang S.J., Srinivasan S., Ye K.;
RT   "Akt phosphorylates MstI and prevents its proteolytic activation,
RT   blocking FOXO3 phosphorylation and nuclear translocation.";
RL   J. Biol. Chem. 282:30836-30844(2007).
RN   [18]
RP   FUNCTION.
RX   PubMed=18328708; DOI=10.1016/j.cub.2008.02.006;
RA   Praskova M., Xia F., Avruch J.;
RT   "MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell
RT   proliferation.";
RL   Curr. Biol. 18:311-321(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-265; SER-320 AND
RP   THR-340, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   REVIEW.
RX   PubMed=19484742; DOI=10.1002/biof.47;
RA   Hergovich A., Hemmings B.A.;
RT   "Mammalian NDR/LATS protein kinases in hippo tumor suppressor
RT   signaling.";
RL   BioFactors 35:338-345(2009).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH TNNI3.
RX   PubMed=18986304; DOI=10.1042/BJ20081340;
RA   You B., Yan G., Zhang Z., Yan L., Li J., Ge Q., Jin J.P., Sun J.;
RT   "Phosphorylation of cardiac troponin I by mammalian sterile 20-like
RT   kinase 1.";
RL   Biochem. J. 418:93-101(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-3; SER-320; THR-340; THR-367; SER-410 AND
RP   SER-414, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   FUNCTION, INTERACTION WITH RASSF2, AND SUBCELLULAR LOCATION.
RX   PubMed=19525978; DOI=10.1038/onc.2009.152;
RA   Cooper W.N., Hesson L.B., Matallanas D., Dallol A., von Kriegsheim A.,
RA   Ward R., Kolch W., Latif F.;
RT   "RASSF2 associates with and stabilizes the proapoptotic kinase MST2.";
RL   Oncogene 28:2988-2998(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   PHOSPHORYLATION AT THR-120.
RX   PubMed=19940129; DOI=10.1074/jbc.M109.059675;
RA   Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S.,
RA   Coppola D., Cheng J.Q.;
RT   "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic
RT   signaling through phosphorylation of threonine 120.";
RL   J. Biol. Chem. 285:3815-3824(2010).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   FUNCTION.
RX   PubMed=21245099; DOI=10.1158/0008-5472.CAN-10-2203;
RA   Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J.,
RA   Truksa J., Dong L.F., Ralph S.J., Neuzil J.;
RT   "Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA
RT   in a FoxO1-dependent manner.";
RL   Cancer Res. 71:946-954(2011).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR.
RX   PubMed=21512132; DOI=10.1158/0008-5472.CAN-10-4532;
RA   Cinar B., Collak F.K., Lopez D., Akgul S., Mukhopadhyay N.K.,
RA   Kilicarslan M., Gioeli D.G., Freeman M.R.;
RT   "MST1 is a multifunctional caspase-independent inhibitor of androgenic
RT   signaling.";
RL   Cancer Res. 71:4303-4313(2011).
RN   [31]
RP   INTERACTION WITH RASSF1, AND ENZYME REGULATION.
RX   PubMed=21199877; DOI=10.1074/jbc.M110.178210;
RA   Guo C., Zhang X., Pfeifer G.P.;
RT   "The tumor suppressor RASSF1A prevents dephosphorylation of the
RT   mammalian STE20-like kinases MST1 and MST2.";
RL   J. Biol. Chem. 286:6253-6261(2011).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SIRT1.
RX   PubMed=21212262; DOI=10.1074/jbc.M110.182543;
RA   Yuan F., Xie Q., Wu J., Bai Y., Mao B., Dong Y., Bi W., Ji G., Tao W.,
RA   Wang Y., Yuan Z.;
RT   "MST1 promotes apoptosis through regulating Sirt1-dependent p53
RT   deacetylation.";
RL   J. Biol. Chem. 286:6940-6945(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   INVOLVEMENT IN TIIAC.
RX   PubMed=22294732; DOI=10.1182/blood-2011-09-378158;
RA   Abdollahpour H., Appaswamy G., Kotlarz D., Diestelhorst J., Beier R.,
RA   Schaffer A.A., Gertz E.M., Schambach A., Kreipe H.H., Pfeifer D.,
RA   Engelhardt K.R., Rezaei N., Grimbacher B., Lohrmann S., Sherkat R.,
RA   Klein C.;
RT   "The phenotype of human STK4 deficiency.";
RL   Blood 119:3450-3457(2012).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-340; THR-387; SER-410
RP   AND SER-414, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-162; GLN-310; MET-312; THR-355 AND
RP   LEU-416.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated, pro-apoptotic kinase which, following
CC       caspase-cleavage, enters the nucleus and induces chromatin
CC       condensation followed by internucleosomal DNA fragmentation. Key
CC       component of the Hippo signaling pathway which plays a pivotal
CC       role in organ size control and tumor suppression by restricting
CC       proliferation and promoting apoptosis. The core of this pathway is
CC       composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in
CC       complex with its regulatory protein SAV1, phosphorylates and
CC       activates LATS1/2 in complex with its regulatory protein MOB1,
CC       which in turn phosphorylates and inactivates YAP1 oncoprotein and
CC       WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its
CC       translocation into the nucleus to regulate cellular genes
CC       important for cell proliferation, cell death, and cell migration.
CC       STK3/MST2 and STK4/MST1 are required to repress proliferation of
CC       mature hepatocytes, to prevent activation of facultative adult
CC       liver stem cells (oval cells), and to inhibit tumor formation (By
CC       similarity). Phosphorylates 'Ser-14' of histone H2B (H2BS14ph)
CC       during apoptosis. Phosphorylates FOXO3 upon oxidative stress,
CC       which results in its nuclear translocation and cell death
CC       initiation. Phosphorylates MOBKL1A, MOBKL1B and RASSF2.
CC       Phosphorylates TNNI3 (cardiac Tn-I) and alters its binding
CC       affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T).
CC       Phosphorylates FOXO1 on 'Ser-212' and regulates its activation and
CC       stimulates transcription of PMAIP1 in a FOXO1-dependent manner.
CC       Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53
CC       deacetylation, thereby promoting p53/TP53 dependent transcription
CC       and apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1.
CC       Phosphorylates AR on 'Ser-650' and suppresses its activity by
CC       intersecting with PKB/AKT1 signaling and antagonizing formation of
CC       AR-chromatin complexes. {ECO:0000250, ECO:0000269|PubMed:11278283,
CC       ECO:0000269|PubMed:11517310, ECO:0000269|PubMed:12757711,
CC       ECO:0000269|PubMed:15109305, ECO:0000269|PubMed:16510573,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:16930133,
CC       ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:18328708,
CC       ECO:0000269|PubMed:18986304, ECO:0000269|PubMed:19525978,
CC       ECO:0000269|PubMed:21212262, ECO:0000269|PubMed:21245099,
CC       ECO:0000269|PubMed:21512132, ECO:0000269|PubMed:8702870,
CC       ECO:0000269|PubMed:8816758}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Inhibited by the C-terminal non-catalytic
CC       region. Activated by caspase-cleavage. Full activation also
CC       requires homodimerization and autophosphorylation of Thr-183.
CC       Activated by RASSF1 which acts by preventing its
CC       dephosphorylation. {ECO:0000269|PubMed:15109305,
CC       ECO:0000269|PubMed:21199877, ECO:0000269|PubMed:8702870}.
CC   -!- SUBUNIT: Homodimer; mediated via the coiled-coil region. Interacts
CC       with NORE1, which inhibits autoactivation. Interacts with and
CC       stabilizes SAV1. Interacts with RASSF1. Interacts with FOXO3.
CC       Interacts with RASSF2 (via SARAH domain). Interacts with AR,
CC       PKB/AKT1, TNNI3 and SIRT1. {ECO:0000269|PubMed:15109305,
CC       ECO:0000269|PubMed:16510573, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:16930133, ECO:0000269|PubMed:17726016,
CC       ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:18986304,
CC       ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:21199877,
CC       ECO:0000269|PubMed:21212262, ECO:0000269|PubMed:21512132}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-367376, EBI-367376;
CC       P31749:AKT1; NbExp=13; IntAct=EBI-367376, EBI-296087;
CC       O95166:GABARAP; NbExp=2; IntAct=EBI-367376, EBI-712001;
CC       Q9H0R8:GABARAPL1; NbExp=2; IntAct=EBI-367376, EBI-746969;
CC       P60520:GABARAPL2; NbExp=2; IntAct=EBI-367376, EBI-720116;
CC       Q9GZQ8:MAP1LC3B; NbExp=7; IntAct=EBI-367376, EBI-373144;
CC       Q9H8S9:MOB1A; NbExp=9; IntAct=EBI-367376, EBI-748229;
CC       Q7L9L4:MOB1B; NbExp=4; IntAct=EBI-367376, EBI-2558745;
CC       Q06830:PRDX1; NbExp=11; IntAct=EBI-367376, EBI-353193;
CC       P35700:Prdx1 (xeno); NbExp=3; IntAct=EBI-367376, EBI-444948;
CC       Q9NS23-2:RASSF1; NbExp=4; IntAct=EBI-367376, EBI-438698;
CC       P50749:RASSF2; NbExp=15; IntAct=EBI-367376, EBI-960081;
CC       Q86WH2:RASSF3; NbExp=6; IntAct=EBI-367376, EBI-2845202;
CC       Q9H2L5:RASSF4; NbExp=6; IntAct=EBI-367376, EBI-2933362;
CC       Q8WWW0:RASSF5; NbExp=7; IntAct=EBI-367376, EBI-367390;
CC       Q8WWW0-2:RASSF5; NbExp=4; IntAct=EBI-367376, EBI-960502;
CC       Q8WWW0-3:RASSF5; NbExp=2; IntAct=EBI-367376, EBI-960507;
CC       Q6ZTQ3:RASSF6; NbExp=4; IntAct=EBI-367376, EBI-2933412;
CC       Q9H4B6:SAV1; NbExp=18; IntAct=EBI-367376, EBI-1017775;
CC       Q14BN4:SLMAP; NbExp=7; IntAct=EBI-367376, EBI-1043216;
CC       Q13188:STK3; NbExp=17; IntAct=EBI-367376, EBI-992580;
CC       Q91VJ4:Stk38 (xeno); NbExp=2; IntAct=EBI-367376, EBI-2527046;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=The caspase-cleaved
CC       form cycles between the nucleus and cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13043-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13043-2; Sequence=VSP_019851, VSP_019852;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels
CC       increase from the normal to the malignant state (at protein
CC       level). Ubiquitously expressed. {ECO:0000269|PubMed:17932490}.
CC   -!- INDUCTION: Activity increases during mitosis.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       Phosphorylation at Thr-120 and Thr-387 by PKB/AKT1, leads to
CC       inhibition of its: kinase activity, nuclear translocation and
CC       autophosphorylation at Thr-183. It also diminishes its cleavage by
CC       caspases and its ability to phosphorylate FOXO3.
CC       {ECO:0000269|PubMed:11278283, ECO:0000269|PubMed:15109305,
CC       ECO:0000269|PubMed:17726016, ECO:0000269|PubMed:19940129}.
CC   -!- PTM: Proteolytically cleaved by caspase-3 during apoptosis at Asp-
CC       326 and Asp-349 resulting in a 37 kDa or a 39 kDa subunit
CC       respectively. The 39 kDa subunit is further cleaved into the 37
CC       kDa form. Proteolytic cleavage results in kinase activation and
CC       nuclear translocation of the truncated form (MST1/N). It is less
CC       likely that cleavage at Asp-349 is a prerequisite for activation
CC       as this site is not conserved in the murine ortholog.
CC       {ECO:0000269|PubMed:11278283}.
CC   -!- DISEASE: T-cell immunodeficiency, recurrent infections, and
CC       autoimmunity with or without cardiac malformations (TIIAC)
CC       [MIM:614868]: A primary T-cell immunodeficiency syndrome
CC       characterized by progressive loss of naive T-cells, recurrent
CC       bacterial, viral, and fungal infections, warts, and abscesses,
CC       autoimmune manifestations, and cardiac malformations, including
CC       atrial septal defect. {ECO:0000269|PubMed:22294732}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH29511.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH58916.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STK4ID42440ch20q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U18297; AAA83254.1; -; mRNA.
DR   EMBL; U60207; AAB17262.1; -; mRNA.
DR   EMBL; AK315238; BAG37665.1; -; mRNA.
DR   EMBL; Z93016; CAB07508.2; -; Genomic_DNA.
DR   EMBL; AL109839; CAB07508.2; JOINED; Genomic_DNA.
DR   EMBL; AL109839; CAI95633.1; -; Genomic_DNA.
DR   EMBL; Z93016; CAI95633.1; JOINED; Genomic_DNA.
DR   EMBL; AL109839; CAI95634.1; -; Genomic_DNA.
DR   EMBL; Z93016; CAI95634.1; JOINED; Genomic_DNA.
DR   EMBL; Z93016; CAI19815.1; -; Genomic_DNA.
DR   EMBL; AL109839; CAI19815.1; JOINED; Genomic_DNA.
DR   EMBL; CH471077; EAW75882.1; -; Genomic_DNA.
DR   EMBL; BC029511; AAH29511.1; ALT_SEQ; mRNA.
DR   EMBL; BC058916; AAH58916.1; ALT_SEQ; mRNA.
DR   EMBL; BC093768; AAH93768.1; -; mRNA.
DR   CCDS; CCDS13341.1; -. [Q13043-1]
DR   RefSeq; NP_006273.1; NM_006282.3. [Q13043-1]
DR   RefSeq; XP_005260590.1; XM_005260533.2. [Q13043-2]
DR   UniGene; Hs.472838; -.
DR   PDB; 2JO8; NMR; -; A/B=432-480.
DR   PDB; 3COM; X-ray; 2.20 A; A/B=2-311.
DR   PDB; 4NR2; X-ray; 2.00 A; A/B/C/D/E/F/G/H=432-480.
DR   PDB; 4OH8; X-ray; 2.28 A; A=432-480.
DR   PDBsum; 2JO8; -.
DR   PDBsum; 3COM; -.
DR   PDBsum; 4NR2; -.
DR   PDBsum; 4OH8; -.
DR   ProteinModelPortal; Q13043; -.
DR   SMR; Q13043; -.
DR   BioGrid; 112665; 65.
DR   DIP; DIP-32491N; -.
DR   IntAct; Q13043; 170.
DR   MINT; MINT-4658525; -.
DR   STRING; 9606.ENSP00000361892; -.
DR   BindingDB; Q13043; -.
DR   ChEMBL; CHEMBL4598; -.
DR   GuidetoPHARMACOLOGY; 2225; -.
DR   iPTMnet; Q13043; -.
DR   PhosphoSitePlus; Q13043; -.
DR   BioMuta; STK4; -.
DR   DMDM; 13124559; -.
DR   EPD; Q13043; -.
DR   MaxQB; Q13043; -.
DR   PaxDb; Q13043; -.
DR   PeptideAtlas; Q13043; -.
DR   PRIDE; Q13043; -.
DR   DNASU; 6789; -.
DR   Ensembl; ENST00000372801; ENSP00000361887; ENSG00000101109. [Q13043-2]
DR   Ensembl; ENST00000372806; ENSP00000361892; ENSG00000101109. [Q13043-1]
DR   GeneID; 6789; -.
DR   KEGG; hsa:6789; -.
DR   UCSC; uc002xnb.4; human. [Q13043-1]
DR   CTD; 6789; -.
DR   DisGeNET; 6789; -.
DR   GeneCards; STK4; -.
DR   H-InvDB; HIX0015851; -.
DR   HGNC; HGNC:11408; STK4.
DR   HPA; CAB004038; -.
DR   HPA; HPA015270; -.
DR   MalaCards; STK4; -.
DR   MIM; 604965; gene.
DR   MIM; 614868; phenotype.
DR   neXtProt; NX_Q13043; -.
DR   OpenTargets; ENSG00000101109; -.
DR   Orphanet; 314689; Combined immunodeficiency due to STK4 deficiency.
DR   PharmGKB; PA36215; -.
DR   eggNOG; KOG0201; Eukaryota.
DR   eggNOG; ENOG410XP9G; LUCA.
DR   GeneTree; ENSGT00810000125395; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q13043; -.
DR   KO; K04411; -.
DR   OMA; AMINEAM; -.
DR   OrthoDB; EOG091G065P; -.
DR   PhylomeDB; Q13043; -.
DR   TreeFam; TF354217; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-2028269; Signaling by Hippo.
DR   SignaLink; Q13043; -.
DR   SIGNOR; Q13043; -.
DR   ChiTaRS; STK4; human.
DR   EvolutionaryTrace; Q13043; -.
DR   GeneWiki; STK4; -.
DR   GenomeRNAi; 6789; -.
DR   PMAP-CutDB; Q13043; -.
DR   PRO; PR:Q13043; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101109; -.
DR   CleanEx; HS_MST1; -.
DR   CleanEx; HS_STK4; -.
DR   ExpressionAtlas; Q13043; baseline and differential.
DR   Genevisible; Q13043; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IGI:MGI.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; TAS:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060706; P:cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IDA:MGI.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0003157; P:endocardium development; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0046621; P:negative regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0001841; P:neural tube formation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0060215; P:primitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:MGI.
DR   GO; GO:0060800; P:regulation of cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR024205; Mst1_SARAH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR011524; SARAH_dom.
DR   Pfam; PF11629; Mst1_SARAH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50951; SARAH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Coiled coil; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    487       Serine/threonine-protein kinase 4.
FT                                /FTId=PRO_0000086691.
FT   CHAIN         1    326       Serine/threonine-protein kinase 4 37kDa
FT                                subunit.
FT                                /FTId=PRO_0000413735.
FT   CHAIN       327    487       Serine/threonine-protein kinase 4 18kDa
FT                                subunit.
FT                                /FTId=PRO_0000413736.
FT   DOMAIN       30    281       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      433    480       SARAH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00310}.
FT   NP_BIND      36     44       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      290    310       {ECO:0000255}.
FT   COMPBIAS    373    378       Poly-Glu.
FT   ACT_SITE    149    149       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      59     59       ATP.
FT   SITE        326    327       Cleavage; by caspase-3.
FT   SITE        349    350       Cleavage; by caspase-3.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.7}.
FT   MOD_RES       3      3       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     120    120       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:19940129}.
FT   MOD_RES     183    183       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15109305}.
FT   MOD_RES     265    265       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     320    320       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     340    340       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     367    367       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     387    387       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17726016}.
FT   MOD_RES     410    410       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     414    414       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     433    433       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9JI11}.
FT   VAR_SEQ     436    462       LKSWTVEDLQKRLLALDPMMEQEIEEI -> KTSQEQQSGK
FT                                DICIQNCQGNLLCRYAF (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_019851.
FT   VAR_SEQ     463    487       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_019852.
FT   VARIANT     162    162       H -> N (in dbSNP:rs55850759).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041123.
FT   VARIANT     310    310       R -> Q (in dbSNP:rs35447878).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041124.
FT   VARIANT     312    312       V -> M (in dbSNP:rs17420378).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:7665586}.
FT                                /FTId=VAR_027040.
FT   VARIANT     355    355       I -> T (in dbSNP:rs35944046).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041125.
FT   VARIANT     416    416       P -> L (in dbSNP:rs33963346).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041126.
FT   MUTAGEN      59     59       K->R: Loss of activity.
FT                                {ECO:0000269|PubMed:15109305,
FT                                ECO:0000269|PubMed:16930133}.
FT   MUTAGEN     175    175       T->A: No effect on activity.
FT                                {ECO:0000269|PubMed:15109305}.
FT   MUTAGEN     177    177       T->A: No effect on activity.
FT                                {ECO:0000269|PubMed:15109305}.
FT   MUTAGEN     183    183       T->A: Loss of activity.
FT                                {ECO:0000269|PubMed:15109305}.
FT   MUTAGEN     326    326       D->N: Resistant to proteolytic cleavage
FT                                by caspase during apoptosis; when
FT                                associated with N-349.
FT                                {ECO:0000269|PubMed:11278283}.
FT   MUTAGEN     349    349       D->N: Resistant to proteolytic cleavage
FT                                by caspase during apoptosis; when
FT                                associated with N-326.
FT                                {ECO:0000269|PubMed:11278283}.
FT   MUTAGEN     444    444       L->P: Loss of homodimerization,
FT                                activation, and autophosphorylation.
FT                                {ECO:0000269|PubMed:15109305}.
FT   CONFLICT    222    222       P -> R (in Ref. 1; AAA83254).
FT                                {ECO:0000305}.
FT   HELIX        19     22       {ECO:0000244|PDB:3COM}.
FT   STRAND       30     35       {ECO:0000244|PDB:3COM}.
FT   STRAND       43     49       {ECO:0000244|PDB:3COM}.
FT   TURN         50     52       {ECO:0000244|PDB:3COM}.
FT   STRAND       55     62       {ECO:0000244|PDB:3COM}.
FT   HELIX        68     78       {ECO:0000244|PDB:3COM}.
FT   STRAND       88     94       {ECO:0000244|PDB:3COM}.
FT   STRAND       97    103       {ECO:0000244|PDB:3COM}.
FT   HELIX       110    117       {ECO:0000244|PDB:3COM}.
FT   HELIX       123    142       {ECO:0000244|PDB:3COM}.
FT   HELIX       152    154       {ECO:0000244|PDB:3COM}.
FT   STRAND      155    157       {ECO:0000244|PDB:3COM}.
FT   STRAND      163    165       {ECO:0000244|PDB:3COM}.
FT   HELIX       188    190       {ECO:0000244|PDB:3COM}.
FT   HELIX       193    196       {ECO:0000244|PDB:3COM}.
FT   STRAND      197    199       {ECO:0000244|PDB:3COM}.
FT   HELIX       205    219       {ECO:0000244|PDB:3COM}.
FT   TURN        223    226       {ECO:0000244|PDB:3COM}.
FT   HELIX       229    238       {ECO:0000244|PDB:3COM}.
FT   HELIX       247    249       {ECO:0000244|PDB:3COM}.
FT   HELIX       252    261       {ECO:0000244|PDB:3COM}.
FT   TURN        266    268       {ECO:0000244|PDB:3COM}.
FT   HELIX       272    275       {ECO:0000244|PDB:3COM}.
FT   HELIX       279    282       {ECO:0000244|PDB:3COM}.
FT   HELIX       287    290       {ECO:0000244|PDB:3COM}.
FT   HELIX       291    297       {ECO:0000244|PDB:3COM}.
FT   HELIX       433    436       {ECO:0000244|PDB:4NR2}.
FT   HELIX       441    478       {ECO:0000244|PDB:4NR2}.
SQ   SEQUENCE   487 AA;  55630 MW;  150758EBC5F77D5C CRC64;
     METVQLRNPP RRQLKKLDED SLTKQPEEVF DVLEKLGEGS YGSVYKAIHK ETGQIVAIKQ
     VPVESDLQEI IKEISIMQQC DSPHVVKYYG SYFKNTDLWI VMEYCGAGSV SDIIRLRNKT
     LTEDEIATIL QSTLKGLEYL HFMRKIHRDI KAGNILLNTE GHAKLADFGV AGQLTDTMAK
     RNTVIGTPFW MAPEVIQEIG YNCVADIWSL GITAIEMAEG KPPYADIHPM RAIFMIPTNP
     PPTFRKPELW SDNFTDFVKQ CLVKSPEQRA TATQLLQHPF VRSAKGVSIL RDLINEAMDV
     KLKRQESQQR EVDQDDEENS EEDEMDSGTM VRAVGDEMGT VRVASTMTDG ANTMIEHDDT
     LPSQLGTMVI NAEDEEEEGT MKRRDETMQP AKPSFLEYFE QKEKENQINS FGKSVPGPLK
     NSSDWKIPQD GDYEFLKSWT VEDLQKRLLA LDPMMEQEIE EIRQKYQSKR QPILDAIEAK
     KRRQQNF
//
